AbbVie says bar for ‘sham litigation’ is too low

03-06-2021

Rory O'Neill

AbbVie says bar for ‘sham litigation’ is too low

Valeriya Zankovych / Shutterstock.com

AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.


AbbVie, FTC, Federal Trade Commission, Supreme Court, sham litigation, generics, competition, Third Circuit

LSIPR